These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 8144400)

  • 1. Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.
    Inaba M; Mitsuhashi J; Kawada S; Nakano H
    Jpn J Cancer Res; 1994 Feb; 85(2):187-93. PubMed ID: 8144400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells.
    Del Bino G; Skierski JS; Darzynkiewicz Z
    Exp Cell Res; 1991 Aug; 195(2):485-91. PubMed ID: 1649059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
    Hirohashi Y; Hidaka K; Sato S; Kuwano M; Kohno K; Hisatsugu T
    Jpn J Cancer Res; 1995 Nov; 86(11):1097-105. PubMed ID: 8567402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment.
    Zucker RM; Adams DJ; Bair KW; Elstein KH
    Biochem Pharmacol; 1991 Nov; 42(11):2199-208. PubMed ID: 1659821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation.
    Del Bino G; Bruno S; Yi PN; Darzynkiewicz Z
    Cell Prolif; 1992 Nov; 25(6):537-48. PubMed ID: 1333822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new action for topoisomerase inhibitors.
    Zucker RM; Elstein KH
    Chem Biol Interact; 1991; 79(1):31-40. PubMed ID: 1647887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
    Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
    Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells.
    Constantinou A; Grdina D; Kiguchi K; Huberman E
    Exp Cell Res; 1992 Nov; 203(1):100-6. PubMed ID: 1330653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
    Kaufmann SH
    Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: detection of DNA strand breaks by flow cytometry using the in situ nick translation assay.
    Gorczyca W; Melamed MR; Darzynkiewicz Z
    Toxicol Lett; 1993 Apr; 67(1-3):249-58. PubMed ID: 8383887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
    Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
    Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
    Del Bino G; Darzynkiewicz Z
    Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
    D'Arpa P; Beardmore C; Liu LF
    Cancer Res; 1990 Nov; 50(21):6919-24. PubMed ID: 1698546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
    Kim JS; Amorino GP; Pyo H; Cao Q; Choy H
    Radiother Oncol; 2002 Jan; 62(1):61-7. PubMed ID: 11830313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
    Jacob S; Aguado M; Fallik D; Praz F
    Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
    Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
    Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors.
    Bertrand R; Solary E; Jenkins J; Pommier Y
    Exp Cell Res; 1993 Aug; 207(2):388-97. PubMed ID: 7688316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells.
    Roberge M; Th'ng J; Hamaguchi J; Bradbury EM
    J Cell Biol; 1990 Nov; 111(5 Pt 1):1753-62. PubMed ID: 2172257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.